EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SLC4A4 as a novel biomarker involved in immune system response and lung adenocarcinoma progression

Siyu Quan, Na Li, Shihai Lian, Yuanyuan Wang, Yang Liu, Jianbo Liu, Zewei Zhang, Dejun Gao, Yun Li

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Siyu Quan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Biomarkers, Tumor, Adenocarcinoma of Lung, Tumor Microenvironment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Altered expression and activity of solute carrier family 4 member 4 (SLC4A4) could affect the growth, survival and metastasis of tumor cells. Currently, the role of SLC4A4 in lung adenocarcinoma (LUAD) immunotherapy and prognosis was not entirely clear. METHODS: We analyzed SLC4A4 expression in LUAD tissues and cell lines using quantitative reverse transcription-polymerase chain reaction, Western blotting, and immunohistochemistry. The effects of SLC4A4 overexpression on angiogenesis, cell migration, invasion, and epithelial-mesenchymal transition were examined. Public databases helped construct a risk model evaluating SLC4A4's expression on LUAD prognosis and immunotherapy response. Additionally, a xenograft model, flow cytometry, and enzyme-linked immunosorbent assay further explored SLC4A4's role in tumor immune microenvironment infiltration. RESULTS: Upregulation of SLC4A4 promoted apoptosis in the LUAD cell line and significantly inhibited the migration and invasive ability of cancer cells (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsBiomarkers, TumorAdenocarcinoma of LungTumor MicroenvironmentCell MovementHumansAnimalsCell Line, TumorMicePrognosisGene Expression Regulation, NeoplasticEpithelial-Mesenchymal TransitionFemaleMice, NudeMaleDisease ProgressionApoptosisXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Immune infiltrationImmune scoreLung adenocarcinomaRisk scoreSLC4A4

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
  • Nephrology Department, Jinan Zhangqiu District People's Hospital, Jinan 250200, China.
  • Out-patient Department, Zaozhuang Municipal Hospital, Zaozhuang 277102, China.
  • The Department of Hospital Infection, Jinan Fifth People's Hospital, Jinan 250022, China.
  • Thoracic Surgery, PLA 80th Group Army Hospital, Weifang 261011, China.
  • Department of Thoracic Surgery, The Fourth People's Hospital of Heze, Heze 274100, China.

Zitieren

APA

Quan, S., Li, N., Lian, S., Wang, Y., Liu, Y., Liu, J., Zhang, Z., Gao, D., & Li, Y. (2024). SLC4A4 as a novel biomarker involved in immune system response and lung adenocarcinoma progression. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112756

Vancouver

Quan S, Li N, Lian S, Wang Y, Liu Y, Liu J, et al. SLC4A4 as a novel biomarker involved in immune system response and lung adenocarcinoma progression. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112756

BibTeX
@article{Quan2024,
  author = {Quan, Siyu and Li, Na and Lian, Shihai and Wang, Yuanyuan and Liu, Yang and Liu, Jianbo and Zhang, Zewei and Gao, Dejun and Li, Yun},
  title = {SLC4A4 as a novel biomarker involved in immune system response and lung adenocarcinoma progression},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112756}
}
Kostenlos starten →